Melatonin Dosage Optimization for Restorative Sleep Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments using melatonin and other melatonergic agents have shown limited effectiveness in improving the restorative quality of sleep for individuals with primary insomnia characterized by non-restorative sleep, as evidenced by previous studies which found no significant alteration in sleep latency, efficiency, or quality.
Innovation Solution
A medicament comprising melatonin or other melatonergic agents, melatonin agonists, and antagonists in effective amounts, combined with pharmaceutically acceptable diluents and additional therapeutic agents, administered through various routes, including oral, parenteral, and transdermal, in a prolonged release formulation to improve both the quality and quantity of sleep.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If melatonin or melatonergic agents are administered to treat primary insomnia, then sleep quality may be improved, but previous studies show no significant alteration in sleep latency, efficiency, or total sleep time
Solution Approach 1:
The patent applies parameter changes by administering melatonin at specific dosages (0.0025 to 50 mg) at optimized timing (evening administration before bedtime) to achieve restorative sleep effects without compromising sleep efficiency or total sleep time. This resolves the contradiction by adjusting the parameters of dosage and timing to simultaneously improve sleep quality while maintaining sleep quantity metrics.
2Quantity of substance
If exogenous melatonin is administered to ameliorate sleep disorders, then nocturnal melatonin concentration increases, but previous studies found no change in sleep quantity or quality measures
Solution Approach 1:
The patent resolves this contradiction by changing the dosage parameter to a wider range (0.0025 to 50 mg) and optimizing administration timing in the evening, which achieves both increased nocturnal melatonin concentration and improved sleep quality measures including restorative sleep, sleep latency, and efficiency.
Solution Approach 2:
The patent employs periodic action through evening administration of melatonin that aligns with the natural circadian rhythm, creating a periodic enhancement of nocturnal melatonin concentration that effectively improves sleep quality without disrupting natural sleep architecture.
3Reliability
If melatonin is given to polysomnographically pre-screened insomniacs, then patients report improved sleep quality, but they believe their total sleep time has been shorter
Solution Approach 1:
The patent resolves this perceptual contradiction by optimizing the dosage parameters (0.0025 to 50 mg) and administration timing to enhance sleep quality without reducing total sleep time. The controlled parameter adjustments ensure that patients experience both improved sleep quality and maintained or enhanced total sleep duration, eliminating the perceived trade-off.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach significantly improves the restorative quality of sleep and daytime alertness in patients with primary insomnia, as demonstrated by improved sleep initiation, reduced daytime fatigue, and enhanced psychomotor skills without adverse effects on sleep architecture.
Implementation Method 1
the natural hormone melatonin has an increased nocturnal concentration in the blood (according to a particular profile, see e.g. U.S. Pat. No. 5,498,423 (Zisapel)), compared with its daytime concentration, and because also a lack of nocturnal melatonin appears to correlate with the existence of sleep disorders
Data Source
AI summary
The invention relates to a medicament, for treating and improving the restorative quality of sleep, in a patient suffering from primary insomnia, which comprises at least one compound selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists, in an effective amount within the range of 0.0025 to 50 mg, and optionally one or more other therapeutically active agents.